HCPCS code J3520 – Edetate disodium, per 150 mg

Key takeaways

HCPCS code J3520 describes edetate disodium, per 150 mg, the chelating agent billed as a Level II J-code for heavy metal toxicity.

Medicare covers J3520 only for documented heavy metal toxicity, primarily lead poisoning. Chelation for cardiovascular or wellness indications is not covered.

Bill units by dividing the total dose administered by 150 mg and rounding up. Missing this calculation is the leading cause of J3520 rejections.

Edetate disodium ships in single-dose ampules, so every J3520 line sent to Medicare carries either the JW or the JZ modifier.

Claims management software like Pabau’s automates the unit math, attaches the JW or JZ modifier, and checks coverage before submission.

What is edetate disodium and why is it used?

Edetate disodium (EDTA) is a chelating agent. It binds heavy metal ions in the bloodstream so the body can excrete them through the kidneys. Clinically, it carries three labeled indications, though only one drives most claims.

• Lead poisoning (plumbism): The primary FDA-recognized indication. Edetate disodium forms a stable complex with lead ions, enabling urinary elimination. It is used in acute and chronic lead toxicity, particularly in pediatric and occupational exposure cases.
• Heavy metal toxicity: Edetate disodium is sometimes used for other heavy metal overloads such as cadmium and manganese. Evidence and payer coverage for those indications are thinner than for lead.
• Hypercalcemia: An older indication, now rare because safer alternatives exist. Payers typically exclude this use from coverage under J3520.

Route of administration is intravenous infusion, typically delivered over several hours in an outpatient or infusion suite setting. Document the infusion start and stop times in the clinical record. Administration CPT codes are time-dependent, and auditors cross-reference those times against the J3520 units billed.

Where J3520 fits in a chelation therapy claim

Chelation therapy describes the intravenous administration of a chelating agent to remove heavy metals from the body. J3520 covers the drug cost only. A complete chelation therapy claim also carries an administration code for the infusion service, and for a first hour that is 96365. Providers billing the drug without the administration code, or the reverse, face routine edits from Medicare and commercial payers alike.

Scope-of-practice rules also decide which provider types can bill the administration component alongside J3520, and they vary by state. A physician or mid-level provider must typically supervise or perform the service for Medicare reimbursement.

2026 Medicare fee schedule for J3520

Medicare Part B reimburses J3520 based on the drug pricing methodology applied to single-source and multi-source drugs. Rates reflect the Average Sales Price (ASP) plus a 6% add-on for separately payable drugs. Because edetate disodium is available from multiple manufacturers and is not a high-volume drug, Medicare payment amounts are modest and subject to annual revision.

The figures below reflect 2026 CMS-published rates. Verify current amounts using the CMS Physician Fee Schedule lookup tool for your specific MAC jurisdiction.

Commercial payers typically set their J3520 reimbursement rates independently, often as a percentage of AWP (average wholesale price) rather than ASP. Always verify rates in your payer contracts before using CMS figures as a proxy.

Medicare coverage policy for chelation therapy

Medicare’s coverage of chelation therapy is narrow. CMS does not recognize chelation as a covered benefit for cardiovascular disease, general wellness, autism, or anti-aging indications. Coverage applies specifically when documented heavy metal toxicity is the diagnosis, supported by laboratory evidence of elevated serum or urine metal levels.

• Covered indication: Acute or chronic lead poisoning (plumbism) with documented lab confirmation and appropriate ICD-10 coding.
• Not covered: Chelation for coronary artery disease, atherosclerosis, or any indication not meeting NCD/LCD criteria for heavy metal toxicity.
• Prior authorization: Most Medicare Administrative Contractors (MACs) require documentation of the clinical indication. Some require prior authorization for repeat sessions. Verify your MAC’s Local Coverage Determination (LCD) before billing.
• Documentation requirement: The clinical record must include lab results, the indication for treatment, and the dose administered. It must also carry the provider’s clinical rationale for choosing chelation.

Practices offering chelation services should confirm their documentation meets payer requirements before billing J3520 to Medicare. A claim for chelation therapy without supporting documentation of heavy metal toxicity is both a denial risk and an audit trigger.

How commercial payers handle chelation claims

Major commercial payers largely mirror Medicare’s restrictive stance on chelation therapy. Blue Cross Blue Shield and UnitedHealthcare have published medical coverage guidelines that limit J3520 reimbursement to documented heavy metal toxicity indications. Coverage for alternative or integrative chelation protocols (heart disease, heavy metal “detox”) is broadly excluded.

• BCBS: Most regional plans exclude chelation therapy except for confirmed heavy metal poisoning with laboratory support.
• UnitedHealthcare: Published coverage policy limits chelation therapy to medically necessary treatment of heavy metal toxicity; wellness or preventive chelation is non-covered.
• Aetna / Cigna: Similar exclusions apply; always verify the current plan-year policy document before assuming coverage.
• Self-pay: For non-covered indications, obtain a signed Advance Beneficiary Notice (ABN) from Medicare patients before proceeding. Commercial patients sign the equivalent financial waiver.

JW and JZ modifiers on a J3520 claim line

CMS mandates the use of JW and JZ modifiers on single-dose containers to account for drug waste. Edetate disodium (Endrate) is supplied in single-dose ampules, so the JW and JZ rules apply to every J3520 claim line. Waste from a multi-dose vial is never billable, and neither modifier applies to one. Failure to append the correct modifier is among the most common J3520 billing errors flagged during MAC audits.

Under CMS policy, one of these two modifiers must appear on every claim line for J3520 submitted to Medicare. Claims missing both modifiers will be rejected on edit. Document the amount administered and the amount discarded in the clinical record. Those figures support the modifier chosen and must be available for auditor review.

ICD-10 diagnosis codes commonly paired with J3520

The ICD-10-CM codes below are the diagnoses that support medical necessity for J3520 claims. Without a covered diagnosis on the claim, payers will deny J3520 as not medically necessary. Select the most specific code available, and check the wider ICD-10-CM code index when the toxicity involves a metal other than lead. Verify the clinical record supports whichever code you choose.

The CDC/NCHS ICD-10-CM web tool provides searchable access to the full tabular list. Coders should also check the seventh character on the code. A means initial encounter, D subsequent, and S sequela, and it must match the visit type in the record.

Reporting the NDC with J3520

Several payers, including many Medicaid programs, require the National Drug Code (NDC) on claims for separately payable drugs. The NDC identifies the manufacturer, product, and package size of the edetate disodium administered. Report the NDC that matches the ampule actually used, never a generic or placeholder number.

Do not fabricate or estimate NDC numbers. The FDA’s NDC Directory is the authoritative source. Verify the NDC against the product dispensed, since generic edetate disodium from different manufacturers carries different 11-digit codes. Where a practice draws from more than one supply run, record the NDC at the point of care, since lot and manufacturer can vary.

Codes you will see alongside J3520

Coders billing chelation therapy or related infusion drug services will encounter the codes below alongside J3520. Knowing when each applies prevents duplicate billing and stops an unclassified code being used where a specific one exists. Confirm your billing system supports J-series drug code lookup and crosswalks each J-code to its companion administration code.

The most important distinction here is between J3520 and J0600. Edetate disodium (J3520) and edetate calcium disodium (J0600) are pharmacologically distinct molecules with different safety profiles. Using the wrong one is a billing error and a clinical documentation error, and it can trigger post-payment review.

How to bill J3520 step by step

Getting J3520 right takes more than picking the correct code. Each step below is a distinct failure point where claims get rejected. Pabau’s medical claims management tools automate the unit math and the modifier choice, which removes manual entry errors at steps 3 and 4. Start with the unit conversion, since that is where most J3520 lines go wrong.

1. Confirm the clinical indication. Verify the diagnosis supports chelation therapy with edetate disodium. Lead poisoning with laboratory confirmation is the primary covered indication. Document the lab result, the serum or urine lead level, and the clinical rationale in the patient record before scheduling the infusion.
2. Verify payer coverage and authorization. Check the patient’s active payer benefits for chelation therapy before the date of service. Obtain prior authorization where required by the MAC LCD or commercial plan. For Medicare patients, confirm no ABN is needed if coverage is expected.
3. Calculate units. Divide the total dose of edetate disodium administered (in mg) by 150. Round up if the result is not a whole number. For example, a 1,500 mg dose equals 10 units of J3520. Never bill a flat one unit per session regardless of dose.
4. Attach the correct modifier. If drug is discarded from the ampule, append modifier JW to the J3520 line. If the full ampule was administered with no waste, append JZ. Document the amount administered and the amount wasted in the clinical note.
5. Pair J3520 with the administration CPT code. Add CPT 96365 for the first hour of IV infusion and CPT 96366 for each additional hour. Ensure start and stop times are in the record to support the administration code.
6. Report the NDC. For Medicaid and NDC-required commercial payers, include the 11-digit NDC from the ampule label in Loop 2410 of the 837P claim. On a paper CMS-1500 it goes in the shaded portion of Box 24A. Include the quantity administered and the unit of measure (ML).
7. Submit and track. After submission, monitor the claim for edits. Common edit responses include unit quantity rejection (step 3 error), missing modifier (step 4), or missing NDC. Address remittance advice denial codes within your payer’s timely filing window.

Common billing errors and denial reasons for J3520

J3520 denials cluster around a predictable set of errors. The table below maps each common denial reason to its root cause and fix. Reviewing your remittance advice for these patterns after the first few claims catches systemic issues before they accumulate.

Practices that get J3520 right on the first pass avoid the cascading delays that come from working denials retroactively. A clean J3520 claim needs a documentation workflow, a pre-submission check, and staff who know the per-150-mg unit rule.

How claims management software keeps J3520 lines clean

In most infusion practices the J3520 line gets built twice. A nurse writes the dose into the treatment note. A coder converts it to units days later, working from whatever that note captured.

Pabau, our practice management software, keeps the claim attached to the record it came from. The patient’s insurer and policy sit on the patient record, so an invoice routes to the right payer without re-keying. When the invoice is ready, Pabau pulls the patient, treatment, and insurer details into a pre-filled submission you review and send.

In the US that submission goes to Claim.MD from inside Pabau. Every claim then carries a visible status, from submitted through to paid or error. So a rejected J3520 line stays traceable. You can see which insurer holds the claim and which treatment note the units came from, without opening a second system.

The result is fewer trips back through the chart to answer a denial, and a chelation claim your coder can reconcile in one place.

Bill J-codes right the first time

Pabau handles J-series drug code billing, unit calculation, modifier attachment, and coverage checks in one workflow. Your J3520 claims go out clean the first time.

Book a demo

Conclusion

J3520 is a narrow code that generates a wide share of avoidable denials, and almost always for the same reason. The unit count on the line does not match the milligrams in the note.

So the fix sits upstream, in the chart. Record the dose, the waste, and the diagnosis properly at the chair. The units, the modifier, and the NDC then follow without a second review. Chelation claims will still get scrutinized, but they will survive it.

Pabau builds those checks into the submission workflow rather than leaving them to a manual coder review. Book a demo to see how J-code units, modifiers, and payer rules are handled in one place.

Continue your research

Want a J3520 claim to pass on the first submission? What makes a clean claim sets out the fields payers check before a claim reaches adjudication.

Not sure what an auditor will ask for? Medical billing compliance covers the documentation, retention, and audit-response duties that come with drug billing.

Want to understand how modern claims tools work end-to-end? What is revenue cycle management explains the full billing lifecycle from charge capture to payment posting.

Looking for guidance on handling denied J-code claims? Denial codes in medical billing maps common CARC denial reasons to corrective actions you can take before refiling.

Frequently asked questions